← Back to Clinical Trials
Recruiting NCT07433660

NCT07433660 WellSpan-THRIVE Cancer QOL Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07433660
Status Recruiting
Phase
Sponsor WellSpan Health
Condition Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2026-02
Primary Completion 2031-02

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000 participants in total. It began in 2026-02 with a primary completion date of 2031-02.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Cancer affects millions of people worldwide and can significantly impact not only survival, but also day-to-day quality of life. Treatments such as surgery, chemotherapy, and radiation can cause side effects like fatigue, pain, and neuropathy, which may affect physical function, emotional well-being, and social relationships. While many studies have examined factors that influence quality of life; such as age, type and stage of cancer, and treatment-related symptoms; there is still a need for tools that more fully reflect patients' lived experiences. This study aims to develop and implement a patient-centered quality of life (QOL) survey designed specifically for individuals with cancer. By directly involving patients in sharing what matters most to them, the survey seeks to provide a more complete and accurate understanding of how cancer and its treatment affect daily life. The results will help patients, families, and healthcare providers better identify needs, guide supportive care, and improve overall well-being throughout the cancer journey.

Eligibility Criteria

Inclusion Criteria: * Age 18 years and above * Primary cancer diagnosis (newly diagnosed within the past 6 months) * Able to sign informed consent. Exclusion Criteria: * Patients with age\<18 years, * Patients with primary non-melanoma skin, neurological malignancies (Brain or brain metastases), and primary hematological malignancies. * Patients with severe cognitive impairment, unable to sign informed consent or unable to complete quality of life questionnaire. * Patients with life expectancy of \<90 days, in the opinion of treating investigator.

Contact & Investigator

Central Contact

Joan K Moore, MSN, RN, OCN, CCRP

✉ jmoore@wellspan.org

📞 717-741-8124

Principal Investigator

Navesh Sharma, DO, PhD, FACRO

PRINCIPAL INVESTIGATOR

WellSpan Health

Frequently Asked Questions

Who can join the NCT07433660 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07433660 currently recruiting?

Yes, NCT07433660 is actively recruiting participants. Contact the research team at jmoore@wellspan.org for enrollment information.

Where is the NCT07433660 trial being conducted?

This trial is being conducted at Chambersburg, United States, Ephrata, United States, Gettysburg, United States, Lebanon, United States and 1 additional location.

Who is sponsoring the NCT07433660 clinical trial?

NCT07433660 is sponsored by WellSpan Health. The principal investigator is Navesh Sharma, DO, PhD, FACRO at WellSpan Health. The trial plans to enroll 1,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology